insights_auto
Pourquoi RARE a-t-elle augmenté de 2,69%?
Approfondirchevron_right
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
17,20 $US
arrow_upward
+2,69%(+0,45) 1J
17,20 $US
0,00% (0,00)
bedtimeAprès clôture
Fermé : 28 oct., 16:00:00 UTC−4 · USD
search
Tous les symboles
| Symbole | Cours | Variation | % variat. |
|---|
insights_autoGénération des principaux insights pour RARE...
Ouverture
16,73 $US
Élevé
17,35 $US
Faible
16,47 $US
Cap. boursière
1,70 Md
Vol. moyen
4,70 M
Volume
2,31 M
+ haut sur 1 an
39,89 $US
+ bas sur 1 an
12,73 $US
BPA
-5,84 $US
Bêta
0,35
Actions en circulation
98,59 M
Nombre d'employés
1 k
Ouverture
16,73 $US
Élevé
17,35 $US
Faible
16,47 $US
Cap. boursière
1,70 Md
Vol. moyen
4,70 M
Volume
2,31 M
+ haut sur 1 an
39,89 $US
+ bas sur 1 an
12,73 $US
BPA
-5,84 $US
Bêta
0,35
Actions en circulation
98,59 M
Nombre d'employés
1 k
Articles
Sources : Web et partenaires du secteur de l'information
Zacks
·
il y a 6 heures
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
Zacks
·
il y a 9 heures
GSK (GSK) Q3 Earnings and Revenues Beat Estimates
Yahoo Finance
·
il y a 1 jour
Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update
Profil
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
À propos de Ultragenyx Pharmaceutical Inc
PDGEmil Kakkis
Employés1,37 k
Date de création2010
Siège socialNovato, Californie, États-Unis
Secteur-
Site Webultragenyx.com